Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365506 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
A Phase 1 study of LQT2 Syndrome, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT02365506 is a Phase 1 study of LQT2 Syndrome that has completed, run by Gilead Sciences. The registered enrollment target is 13 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02365506, a Phase 1 study of LQT2 Syndrome, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eleclazine
Study Locations (1)
New York
- University of Rochester Medical Center/Strong Memorial Hospital - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-07-20 |
| Est. Completion | 2016-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365506
The ClinicalTrials.gov registry entry for NCT02365506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with LQT2 Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02365506 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02365506 about?
NCT02365506 is a clinical study titled "Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome". The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.
What is the current status of trial NCT02365506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-07-20. Estimated completion is 2016-06-13.
What conditions does trial NCT02365506 study?
This clinical trial studies the following conditions: LQT2 Syndrome.
What interventions are being tested in trial NCT02365506?
The interventions under investigation include: Placebo (DRUG), Eleclazine (DRUG).
Who is sponsoring clinical trial NCT02365506?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02365506 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.